Quick Answer
Forte Biosciences, Inc. reported Cash and Equivalents of $76.96 million for fiscal year 2025.
Forte Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $76.96M | +246.0% |
| 2024 | $22.24M | -40.1% |
| 2023 | $37.12M | -9.7% |
| 2022 | $41.10M | -2.2% |
| 2021 | $42.04M | -28.5% |
| 2020 | $58.77M | +746.9% |
| 2019 | $6.94M | -83.0% |
| 2018 | $40.81M | +13.6% |
| 2017 | $35.93M | +552.1% |
| 2016 | $5.51M | -32.4% |
| 2015 | $8.15M | +93.9% |
| 2014 | $4.20M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $93.41M | +470.9% | -12.0% |
| June 30, 2025 | $106.14M | +333.3% | +131.5% |
| March 31, 2025 | $45.86M | +50.6% | +106.1% |
| December 31, 2024 | $22.24M | -40.1% | +35.9% |
| September 30, 2024 | $16.36M | -64.6% | -33.2% |
| June 30, 2024 | $24.50M | +19.9% | -19.5% |
| March 31, 2024 | $30.44M | -15.2% | -18.0% |
| December 31, 2023 | $37.12M | -9.7% | -19.6% |
- Forte Biosciences, Inc. showed an increase of +246.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, Forte Biosciences, Inc.’s cash and equivalents has grown by 1730.6% (from $4.20 million to $76.96 million).
- The most recent figure is from Forte Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: